Chemokine Therapeutics Announces Patent Issuance for Chemokine Analogs for the Treatment of Human Disease

31-Aug-2006

Chemokine Therapeutics Corp. announced that the United States Patent and Trademark Office has issued U.S. Patent 7,091,310 B2 relating to chemokine analogs for the treatment of human disease.

The patent covers chemokine analogs (peptide agonists and antagonists of chemokines) that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders, including autoimmune diseases, acute chronic inflammation, cancer, cardiovascular disease, infectious disease and inflammatory disorders such as rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, atherosclerosis, psoriasis, rhinitis, autoimmunity and organ transplant rejection.

Dr. Hassan Salari, President and Chief Executive Officer of Chemokine Therapeutics, stated, "This new patent grant reinforces our overriding strategy to broaden the proprietary scope of our drug development platform while helping to further solidify our intellectual property position."

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

Astex ranked top biotech company for the second year running in The Sunday Times Microsoft Tech Track 100

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

Biotage AB Acquires Separtis Holding AG for 1.4M Euros (13M SEK) and Completes EU Distribution Consolidation

A*STAR Scientists Discover Key Component in the Mother's Egg Critical for Survival of Newly Formed Embryo

Development of wireless multi-parameter monitoring system for viruses and very slow growing microorganisms - Biophage Pharma signs collaborates with National Taiwan University

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

ES Cell International and ITI Life Sciences sign Licence Agreement for use of novel Stem Cell Technologies

To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases

Intercell reports positive results from its Phase II Pseudomonas aeruginosa investigational vaccine study